Evaxion Short Long Term Debt vs Net Receivables Analysis

EVAX Stock

USD 1.57 0.04 2.48%

Evaxion Biotech financial indicator trend analysis is much more than just examining Evaxion Biotech AS latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evaxion Biotech AS is a good investment. Please check the relationship between Evaxion Biotech Short Long Term Debt and its Net Receivables accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evaxion Biotech AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Short Long Term Debt vs Net Receivables

Short Long Term Debt vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evaxion Biotech AS Short Long Term Debt account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Evaxion Biotech's Short Long Term Debt and Net Receivables is 0.64. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Evaxion Biotech AS, assuming nothing else is changed. The correlation between historical values of Evaxion Biotech's Short Long Term Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Evaxion Biotech AS are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Short Long Term Debt i.e., Evaxion Biotech's Short Long Term Debt and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Net Receivables

Most indicators from Evaxion Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evaxion Biotech AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evaxion Biotech AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Issuance Of Capital Stock is likely to rise to about 15.2 M in 2024, whereas Tax Provision is likely to drop (825.3 K) in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	343.5K	571.3K	615.9K	330.1K
Interest Income	2.0M	2.8M	2.3M	1.4M

Depreciation And Amortization Interest Income

Evaxion Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Net Tangible Assets	Other Assets
Total Assets		0.19	0.13	0.14	0.43	-0.07	-0.15	0.05	0.12	0.24	-0.01	-0.24	0.24	0.25	-0.08	-0.24	-0.09	0.09	-0.09	0.16	0.29	0.17	0.06	0.0	0.01	0.88
Short Long Term Debt Total	0.19		0.85	0.81	-0.16	0.51	0.24	-0.78	0.41	0.25	0.39	0.64	0.25	-0.67	-0.6	0.71	0.53	0.18	0.89	0.11	0.36	-0.09	0.47	0.68	0.64	0.02
Other Current Liab	0.13	0.85		0.62	-0.16	0.59	0.18	-0.94	0.64	0.23	0.6	0.75	0.23	-0.62	-0.64	0.89	0.59	0.42	0.9	0.09	0.35	0.0	-0.01	0.83	0.85	-0.06
Total Current Liabilities	0.14	0.81	0.62		-0.26	0.48	-0.05	-0.6	0.59	0.45	0.56	0.53	0.45	-0.77	-0.83	0.54	0.46	0.47	0.79	0.34	0.45	0.1	0.68	0.58	0.56	-0.11
Total Stockholder Equity	0.43	-0.16	-0.16	-0.26		-0.83	0.65	0.48	-0.46	-0.72	-0.6	-0.71	-0.72	0.35	0.43	-0.53	-0.82	-0.34	-0.47	-0.77	-0.7	-0.72	0.01	-0.48	-0.58	0.79
Property Plant And Equipment Net	-0.07	0.51	0.59	0.48	-0.83		-0.51	-0.81	0.71	0.76	0.79	0.93	0.76	-0.44	-0.6	0.78	1.0	0.47	0.74	0.72	0.79	0.67	-0.09	0.86	0.86	-0.49
Net Debt	-0.15	0.24	0.18	-0.05	0.65	-0.51		0.04	-0.42	-0.88	-0.45	-0.21	-0.88	0.03	0.38	0.01	-0.47	-0.41	0.03	-0.93	-0.81	-0.97	0.12	-0.12	-0.33	0.26
Retained Earnings	0.05	-0.78	-0.94	-0.6	0.48	-0.81	0.04		-0.73	-0.41	-0.74	-0.92	-0.41	0.63	0.67	-0.98	-0.81	-0.49	-0.94	-0.31	-0.51	-0.23	0.07	-0.92	-0.94	0.33
Accounts Payable	0.12	0.41	0.64	0.59	-0.46	0.71	-0.42	-0.73		0.61	0.98	0.67	0.61	-0.4	-0.77	0.69	0.66	0.93	0.66	0.55	0.61	0.51	-0.12	0.73	0.81	-0.23
Cash	0.24	0.25	0.23	0.45	-0.72	0.76	-0.88	-0.41	0.61		0.64	0.52	1.0	-0.35	-0.67	0.33	0.72	0.49	0.4	0.99	0.98	0.93	0.11	0.46	0.63	-0.25
Non Current Assets Total	-0.01	0.39	0.6	0.56	-0.6	0.79	-0.45	-0.74	0.98	0.64		0.73	0.64	-0.38	-0.72	0.73	0.74	0.91	0.68	0.6	0.63	0.56	-0.13	0.73	0.81	-0.38
Non Currrent Assets Other	-0.24	0.64	0.75	0.53	-0.71	0.93	-0.21	-0.92	0.67	0.52	0.73		0.52	-0.59	-0.6	0.92	0.94	0.4	0.87	0.46	0.57	0.38	-0.06	0.94	0.89	-0.55
Cash And Short Term Investments	0.24	0.25	0.23	0.45	-0.72	0.76	-0.88	-0.41	0.61	1.0	0.64	0.52		-0.35	-0.67	0.33	0.72	0.49	0.4	0.99	0.98	0.93	0.11	0.46	0.63	-0.25
Net Receivables	0.25	-0.67	-0.62	-0.77	0.35	-0.44	0.03	0.63	-0.4	-0.35	-0.38	-0.59	-0.35		0.84	-0.64	-0.43	-0.25	-0.77	-0.25	-0.36	-0.07	-0.49	-0.54	-0.65	0.44
Common Stock Shares Outstanding	-0.08	-0.6	-0.64	-0.83	0.43	-0.6	0.38	0.67	-0.77	-0.67	-0.72	-0.6	-0.67	0.84		-0.62	-0.55	-0.66	-0.75	-0.58	-0.66	-0.43	-0.35	-0.62	-0.79	0.28
Non Current Liabilities Total	-0.24	0.71	0.89	0.54	-0.53	0.78	0.01	-0.98	0.69	0.33	0.73	0.92	0.33	-0.64	-0.62		0.78	0.48	0.93	0.24	0.42	0.17	-0.1	0.87	0.91	-0.48
Capital Lease Obligations	-0.09	0.53	0.59	0.46	-0.82	1.0	-0.47	-0.81	0.66	0.72	0.74	0.94	0.72	-0.43	-0.55	0.78		0.4	0.74	0.69	0.76	0.63	-0.09	0.87	0.84	-0.49
Other Current Assets	0.09	0.18	0.42	0.47	-0.34	0.47	-0.41	-0.49	0.93	0.49	0.91	0.4	0.49	-0.25	-0.66	0.48	0.4		0.45	0.46	0.47	0.44	-0.13	0.43	0.59	-0.2
Total Liab	-0.09	0.89	0.9	0.79	-0.47	0.74	0.03	-0.94	0.66	0.4	0.68	0.87	0.4	-0.77	-0.75	0.93	0.74	0.45		0.29	0.49	0.13	0.25	0.84	0.86	-0.36
Net Invested Capital	0.16	0.11	0.09	0.34	-0.77	0.72	-0.93	-0.31	0.55	0.99	0.6	0.46	0.99	-0.25	-0.58	0.24	0.69	0.46	0.29		0.95	0.96	0.07	0.36	0.54	-0.31
Total Current Assets	0.29	0.36	0.35	0.45	-0.7	0.79	-0.81	-0.51	0.61	0.98	0.63	0.57	0.98	-0.36	-0.66	0.42	0.76	0.47	0.49	0.95		0.89	0.07	0.5	0.71	-0.2
Net Working Capital	0.17	-0.09	0.0	0.1	-0.72	0.67	-0.97	-0.23	0.51	0.93	0.56	0.38	0.93	-0.07	-0.43	0.17	0.63	0.44	0.13	0.96	0.89		-0.19	0.3	0.49	-0.28
Short Term Debt	0.06	0.47	-0.01	0.68	0.01	-0.09	0.12	0.07	-0.12	0.11	-0.13	-0.06	0.11	-0.49	-0.35	-0.1	-0.09	-0.13	0.25	0.07	0.07	-0.19		-0.09	-0.13	0.04
Common Stock	0.0	0.68	0.83	0.58	-0.48	0.86	-0.12	-0.92	0.73	0.46	0.73	0.94	0.46	-0.54	-0.62	0.87	0.87	0.43	0.84	0.36	0.5	0.3	-0.09		0.87	-0.29
Net Tangible Assets	0.01	0.64	0.85	0.56	-0.58	0.86	-0.33	-0.94	0.81	0.63	0.81	0.89	0.63	-0.65	-0.79	0.91	0.84	0.59	0.86	0.54	0.71	0.49	-0.13	0.87		-0.36
Other Assets	0.88	0.02	-0.06	-0.11	0.79	-0.49	0.26	0.33	-0.23	-0.25	-0.38	-0.55	-0.25	0.44	0.28	-0.48	-0.49	-0.2	-0.36	-0.31	-0.2	-0.28	0.04	-0.29	-0.36

Click cells to compare fundamentals

Evaxion Biotech Account Relationship Matchups

Evaxion Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.1M	12.0M	40.2M	(58.9M)	12.9M	13.5M
Short Long Term Debt Total	36K	20K	3.7M	2.3M	10.9M	11.4M
Other Current Liab	1.0M	1.2M	1.0M	1.2M	3.9M	4.1M
Total Current Liabilities	1.7M	4.9M	4.3M	3.8M	7.1M	5.0M
Total Stockholder Equity	9.4M	7.0M	(50.4M)	(72.7M)	(4.7M)	(5.0M)
Property Plant And Equipment Net	126K	457K	5.4M	4.7M	4.3M	2.4M
Net Debt	(9.5M)	(5.8M)	(28.5M)	(10.9M)	5.3M	5.6M
Retained Earnings	(15.8M)	(27.3M)	(50.4M)	(72.7M)	(108.0M)	(102.6M)
Accounts Payable	646K	3.7M	2.8M	2.1M	2.7M	1.9M
Cash	9.6M	5.8M	32.2M	13.2M	5.6M	5.3M
Non Current Assets Total	126K	6.1M	5.5M	5.0M	4.5M	3.4M
Cash And Short Term Investments	9.6M	5.8M	32.2M	13.2M	5.6M	5.3M
Net Receivables	931K	1.8M	1.9M	789K	1.1M	1.1M
Liabilities And Stockholders Equity	11.1M	12.0M	(42.7M)	(58.9M)	12.9M	13.5M
Non Current Liabilities Total	682K	2.7M	3.4M	10.0M	10.5M	11.1M
Capital Lease Obligations	36K	20K	2.5M	2.3M	2.2M	1.1M
Other Current Assets	468.0K	6.3M	3.2M	2.5M	1.7M	2.3M
Total Liab	1.7M	4.9M	7.7M	13.7M	17.6M	18.5M
Net Invested Capital	9.4M	7.0M	33.6M	16.3M	3.9M	3.7M
Total Current Assets	11.0M	5.8M	34.7M	14.0M	8.4M	13.3M
Accumulated Other Comprehensive Income	22.7M	31.7M	79.1M	(3.7M)	(3.8M)	(3.6M)
Net Working Capital	9.2M	6.0M	30.4M	13.2M	1.3M	1.2M
Short Term Debt	36K	40K	440K	439K	485K	460.8K
Common Stock	2.5M	2.6M	3.8M	3.9M	5.9M	3.6M
Other Assets	25K	694K	191K	(78.0M)	134.0	140.7
Inventory	(6.0)	(6.9M)	(1.9M)	(2.5M)	(2.2M)	(2.4M)
Other Stockholder Equity	(169K)	34.3M	(82.9M)	80.7M	101.1M	106.2M
Capital Stock	2.5M	2.6M	3.8M	3.9M	5.9M	3.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evaxion Short Long Term Debt vs Net Receivables Analysis

Short Long Term Debt vs Net Receivables

Short Long Term Debt vs Net Receivables Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Net Receivables

Evaxion Biotech fundamental ratios Correlations

Evaxion Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evaxion Biotech fundamental ratios Accounts

Also Currently Popular

Additional Tools for Evaxion Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Net Invested Capital	+ 0.99	Cash
Net Invested Capital	+ 0.99	Cash And Short Term Investments
Non Current Assets Total	+ 0.98	Accounts Payable
Total Current Assets	+ 0.98	Cash

Non Current Liabilities Total	- 0.98	Retained Earnings
Net Working Capital	- 0.97	Net Debt
Net Tangible Assets	- 0.94	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab
Net Invested Capital	- 0.93	Net Debt